World's Best Scientists 2026 revealed!
Olivier Bouché

Olivier Bouché

D-Index & Metrics

Medicine

D-Index
86
Citations
46683
World Ranking
13856
National Ranking
447

Overview

Olivier Bouché is affiliated with CHU de Reims in France and has a substantial research output in the field of medicine, with a pronounced focus on oncology. Their work spans across oncology, pulmonary and respiratory medicine, surgery, cancer research, and pathology and forensic medicine.

The main topics of Bouché's research include colorectal cancer treatments and studies, gastric cancer management and outcomes, pancreatic and hepatic oncology research, colorectal and anal carcinomas, cancer genomics and diagnostics, gastrointestinal tumor research and treatment, and genetic factors in colorectal cancer.

Bouché has frequently published in a variety of academic venues, with notable publication counts in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Digestive and Liver Disease
  • European Journal of Cancer
  • Cancers

Recent publications include:

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial (2021, The Lancet Oncology)
  • Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (2022, JAMA Oncology)
  • Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. (2020, Journal of Clinical Oncology)
  • Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) (2020, European Journal of Cancer)
  • Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR) (2020, Digestive and Liver Disease)

Bouché collaborates regularly with a group of coauthors contributing frequently across various studies. Prominent coauthors include:

  • David Tougeron
  • Thierry Lecomte
  • Julien Taïeb
  • Thomas Aparicio
  • Côme Lepage

The interdisciplinary nature of Bouché's work integrates clinical oncology, surgical approaches, and cancer diagnostics aimed at improving outcomes in gastrointestinal cancers. Their presence in high-impact journals and collaboration with other researchers underscores a consistent involvement in advancing cancer research and clinical guidelines.

Best Publications

  • FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

    Thierry Conroy;Françoise Desseigne;Marc Ychou;Olivier Bouché

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

    Marc Ychou;Valérie Boige;Jean-Pierre Pignon;Thierry Conroy

  • Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

    Jean-Pierre Gérard;Thierry Conroy;Franck Bonnetain;Olivier Bouché

  • KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

    Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre

  • Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102

    Laurent Bedenne;Pierre Michel;Olivier Bouché;Chantal Milan

  • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

    Jaafar Bennouna;Javier Sastre;Dirk Arnold;Pia Österlund

  • Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial

    Pascal Hammel;Florence Huguet;Jean-Luc van Laethem;David Goldstein

  • Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

    Jean-Pierre Gérard;David Azria;Sophie Gourgou-Bourgade;Isabelle Martel-Laffay

  • Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

    B. Chauffert;F. Mornex;Franck Bonnetain;P. Rougier

  • Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

    Pierre Laurent-Puig;Anne Cayre;Gilles Manceau;Emmanuel Buc

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

    Thierry Conroy;Jean-François Bosset;Pierre-Luc Etienne;Emmanuel Rio

  • Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.

    Guillaume Portier;Dominique Elias;Olivier Bouche;Philippe Rougier

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients

    Valerie Taly;Deniz Pekin;Deniz Pekin;Leonor Benhaim;Steve K. Kotsopoulos

  • Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

    Sophie Gourgou-Bourgade;Caroline Bascoul-Mollevi;Françoise Desseigne;Marc Ychou

  • Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

    Jean-Pierre Gérard;David Azria;Sophie Gourgou-Bourgade;Isabelle Martel-Lafay

  • Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

    Thierry Conroy;Marie-Pierre Galais;Jean-Luc Raoul;Olivier Bouché

  • Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen

    Thierry André;Mohamed A. Bensmaine;Christophe Louvet;Eric François

  • Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

    Josep Tabernero;Heinz Josef Lenz;Salvatore Siena;Alberto Sobrero

Frequent Co-Authors

Marc Ychou
Marc Ychou University of Montpellier
Thierry André
Thierry André Université Paris Cité
Julien Taieb
Julien Taieb Université Paris Cité
Michel Ducreux
Michel Ducreux Institut Gustave Roussy
Christophe Borg
Christophe Borg Centre Hospitalier Universitaire de Besançon
Valérie Boige
Valérie Boige Institut Gustave Roussy
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité
François Ghiringhelli
François Ghiringhelli Centre Georges François Leclerc
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online medical degrees opens up a variety of flexible options for students at different stages of their healthcare careers. For registered nurses looking to advance their education without attending in-person clinicals, online rn to bsn programs without clinical requirements offer a way to earn a bachelor’s degree on your own schedule.

Nurses aiming to reach the highest levels of clinical practice should consider accelerated dnp programs, which fast-track their journey to a Doctor of Nursing Practice. These options appeal to professionals seeking a quick transition to advanced roles.

If you are searching for the most accessible paths to doctoral qualifications, dnp programs vary in length, format, and entry requirements, making it easier to find one that fits your background and goals.

Entry-level healthcare professionals can also benefit from lpn accelerated program options. These online courses allow students to enter the workforce quickly while maintaining the flexibility needed for personal commitments.

Best Scientists Citing Olivier Bouché

Trending Scientists

Recently Published Articles